# Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody

> **NCT01430429** · PHASE2 · TERMINATED · sponsor: **Light Chain Bioscience - Novimmune SA**

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** NI-0801

## Key facts

- **NCT ID:** NCT01430429
- **Lead sponsor:** Light Chain Bioscience - Novimmune SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430429, "Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01430429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*